Compare TG Therapeutics Inc (TGTX) vs Roundhill S&P 500 0DTE Covered Call Strategy ETF (XDTE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Roundhill S&P 500 0DTE Covered Call Strategy ETF — how do they compare? TG Therapeutics Inc trades at $55.37 (market cap $8.16B), while Roundhill S&P 500 0DTE Covered Call Strategy ETF trades at $38.71 (market cap $330.98M). The key difference: TG Therapeutics Inc is far larger — about 24.7× Roundhill S&P 500 0DTE Covered Call Strategy ETF's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Roundhill S&P 500 0DTE Covered Call Strategy ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold TG Therapeutics Inc for 16 Days and Roundhill S&P 500 0DTE Covered Call Strategy ETF for 54 Days on average.
| TGTX | XDTE | |
|---|---|---|
Market Cap | $8.16B | $330.98M |
Volume | 1,735,121 | 194,030 |
Sector | Health | Income / Options Overlay |
52-Week High | $59.06 | $44.76 |
52-Week Low | $26.94 | $36.00 |
Typical Hold Time | 16 Days | 54 Days |
Enterprise Value | $8.37B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $53.34, up 0.74% today, but faces bearish technical signals despite strong profitability metrics like a 55.22% net income margin. Recent earnings misses and a shareholder investigation create headwinds, though revenue growth and a high analyst buy consensus of 84.62% suggest underlying strength. The stock's current price is near key support at $52, with resistance at $54.
The outlook is mixed: robust revenue growth and institutional buying support upside toward the $80.50 consensus target, but earnings misses and legal risks pose challenges. Investors should weigh the company's MS therapy momentum against execution and regulatory uncertainties for balanced risk-reward assessment.
XDTE trades at $38.71, down 0.32% on the day, with a bullish technical signal from moving averages but bearish oscillators. The stock shows strong weekly dividend activity, though financial ratios are not disclosed. Recent news highlights its role in weekly income ETF strategies but questions the sustainability of its high yield.
Outlook is mixed; the fund's covered call strategy offers income but faces risks from overnight gaps and fee comparisons. Investors should weigh the attractive yield against potential capital erosion and competitive pressures in the ETF space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Roundhill S&P 500 0DTE Covered Call Strategy ETF
XDTE is an actively managed ETF that utilizes a synthetic covered call strategy on the S&P 500 Index using zero-days-to-expiration (0DTE) options. It seeks to provide high weekly income and overnight exposure to the index while mitigating some volatility through daily option premium harvesting.
Read more on XDTE →
